Search clinical trials for: CP-101

Total 6649 results

Emerald Health Pharmaceuticals

Completed

To Evaluate the Safety and Tolerability, Pharmacokinetics, Food-effect and Pharmacodynamics of EHP-101 in Healthy Volunteers

Healthy

Australia
Rhode Island Hospital

Active, not recruiting

Mobile Integrated Healthcare and Community Paramedicine

Myocardial Infarction | Pneumonia | Hospital Readmission | COPD
Cliniques universitaires Saint-Luc- Université...

Terminated

A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma

Head and Neck Cancer

Belgium
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Pfizer

Completed

Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States, Canada
Xeno Biosciences

Not yet recruiting

A Phase 1b Study to Evaluate the Safety of XEN-101

Obesity
Anbogen Therapeutics, Inc.

Recruiting

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

Non Small Cell Lung Cancer | Advanced Solid Tumor | HER2 Mutations

Taiwan
Dyne Therapeutics

Recruiting

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 (ACHIEVE)

Myotonic Dystrophy Type 1 (DM1)

United Kingdom, France, Netherlands, Italy, Germany, New Zealand
Kanyos Bio, Inc., a wholly-owned subsidiary of...

Completed

Assessment of KAN-101 in Celiac Disease (ACeD)

Celiac Disease

United States
Xeno Biosciences

Completed

A Phase 1 Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of XEN-101

Healthy

Hungary
Bright Minds Biosciences Pty Ltd

Completed

A 3-Part Study to Evaluate the Safety, Tolerability, PK, and Food Effect of BMB-101 in Healthy Volunteers

Healthy

Australia
Novartis Gene Therapies

Completed

Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1

Spinal Muscular Atrophy 1

United States
Teres Bio, Inc.

Completed

Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis

Atopic Dermatitis

United States
Dynavax Technologies Corporation

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

Healthy

United States
Auris Medical, Inc.

Completed

AM-101 in the Treatment of Acute Tinnitus 2 (TACTT2)

Tinnitus

United States
Arava Bio Tech Ltd.
Cato Research

Unknown

Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness Wounds

Wounds and Injuries

United States
Vicept Therapeutics, Inc.
Accenture

Completed

Dose Response Study of Patients With Erythematous Rosacea

Erythematous (Type One) Rosacea

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma and other conditions

United States
AL-S Pharma

Recruiting

A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Korea, Republic of, United States, Canada, Germany, Sweden, Belgium
QurAlis Corporation

Completed

A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Participants

Healthy Volunteers

Netherlands
Veloxis Pharmaceuticals

Completed

A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

Healthy Volunteers

United States
Inversago Pharma Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects

Pharmacokinetic

Canada
Acanthas Pharma Inc

Withdrawn

A Study of Single Ascending Doses of STAR-101 in Healthy Participants

Healthy Volunteers
Alpine Immune Sciences, Inc.
Clinical Network Services (CNS) Pty Ltd

Completed

Adult Healthy Volunteers Study to Evaluate ALPN-101 Safety

Healthy Volunteers

Australia
Arava Bio Tech Ltd.

Unknown

Safety and Efficacy of Topical AR/101 Compared With Placebo, in Accelerating Granulation Tissue Formation of Hard-to-heal Wounds

Wounds | Other Ulcers Wounds and Skin Problems

Israel
Janssen Research & Development, LLC
Hoffmann-La Roche

Terminated

Safety and Efficacy of EVT 101 in Treatment-Resistant Depression

Depression

United States
Minerva Neurosciences

Completed

Pharmacokinetic Study of MIN-101 in Healthy Subjects

Schizophrenia

United Kingdom
Alaunos Therapeutics

Unknown

A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b

Multiple Myeloma

United States
Alaunos Therapeutics

Unknown

A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

HEPATOCELLULAR CARCINOMA

United States
Mozart Therapeutics Australia Pty Ltd

Not yet recruiting

Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients

Type 1 Diabetes | Celiac Disease | Healthy Volunteers

Australia
CorrectSequence Therapeutics Co., Ltd

Recruiting

A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major

Beta-Thalassemia Major

China
Children's Hospital of Fudan University
CorrectSequence Therapeutics Co., Ltd

Recruiting

Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major

Beta-Thalassemia

China
Tvardi Therapeutics, Incorporated

Recruiting

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States
Transposon Therapeutics, Inc.

Recruiting

TPN-101 in Aicardi-Goutières Syndrome (AGS)

Aicardi-Goutières Syndrome (AGS)

United Kingdom, France, Italy
Wugen, Inc.

Recruiting

A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Australia
Corat Therapeutics Gmbh

Recruiting

Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19

Covid19

Germany
Canadian Cancer Trials Group
Canadian Cancer Society (CCS); ATGen Canada Inc; Ontario Institute for Cancer... and other collaborators

Active, not recruiting

Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (COV-IMMUNO)

Covid-19 | Cancer

Canada
Auris Medical AG

Completed

AM-101 in the Treatment of Acute Tinnitus 3 (TACTT3)

Tinnitus

Germany
1ST Biotherapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

Parkinson's Disease

United States
101 Therapeutics

Active, not recruiting

Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects

Virus Diseases | COVID-19 | Infectious Disease | Glucocorticoids Toxicity

India
Sentien Biotechnologies, Inc.

Active, not recruiting

A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy

Acute Kidney Injury

United States
InQpharm Group

Completed

Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea

Diarrhoea

Germany
InQpharm Group

Completed

IQP-PO-101 for the Regulation of Bowel Movement Frequency

Constipation | Irregular Bowel Movement Frequency

Germany
Norgine

Completed

A Study to Evaluate the Safety of TZP-101 (IV Ulimorelin) Administered Post-Operatively in Patients Who Have Undergone Partial Bowel Resection

Postoperative Ileus
Alaunos Therapeutics

Completed

Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

Hematologic Neoplasms | Non-Hodgkin's Lymphoma | Bone Marrow Neoplasms

United States
Cyrenaic Pharmaceuticals

Completed

Study of CYR-101 in Patients With Schizophrenia

Schizophrenia

France
4SC AG

Completed

SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease (ENTRANCE)

Inflammatory Bowel Disease (IBD)

Germany, Bulgaria, Romania
Evotec Neurosciences GmbH
Richmond Pharmacology Limited

Completed

The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function

Human Volunteers

United Kingdom
Eleusis Therapeutics
Beckley Psytech Pty Ltd

Recruiting

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression

Depression | Healthy Volunteers | Major Depressive Disorder

United Kingdom
Kythera Biopharmaceuticals

Completed

A Study to Assess Injection Comfort of Two Formulations of ATX-101

Healthy

United States

Search clinical trials for: CP-101

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations